Side effects of drugs studied on ant models: a mini review

Abstract

Using ants as models, we studied until now the side effects of 47 products used by humans and, over these studies we published five summaries of our main findings. After that, we studied the side effects of six other drugs used by humans, and we here summarize these lastly obtained results. These six other drugs were dextromethorphan, amitriptylin, escitalopram, fluvoxamine, ivermectin, and indapamide. For each of them, we found side effects similar to those reported for humans, but we also observed side effects not yet mentioned for humans. They concern among others the locomotion, the activity, the sensory perception, the social relationships and the learning. Practitioners and pharmacists should take cognizance of our works for more adequately and safely used the six drugs we examined. Our six works are published and thus available, but they can also be provided by the author(s). All over our studies, ants appeared to be excellent biological models; the experiments could be made easily, rapidly and at lost cost, while providing statistically significant results.

Keywords: amitriptylin, cognition, dextromethorphan, escitalopram, fluvoxamine, indapamide, ivermectin, social interactions

Abbreviations: ang.deg./cm, angular degrees per centimeter; cm, centimeter; mm, millimeter; mm/s, millimeter per second; mg, milligram; ml, milliliter; χ², chi square; df, degree of freedom; P, level of probability

Introduction

Medicinal drugs, though often essential for ill humans, have generally side adverse effects which must be known and taken into account during the patient’s treatment. Using ants as models, we examined such side effects of until now 47 drugs, and, for the readers’ convenience, in addition to the publication of each of these works, we summarized our main findings in up to day five papers. After our last published summary, we still examined the side effects of six drugs, and we here summarize these new results in a sixth short paper. Working on ants as models, we could precisely defined some kinds of effects, such as those on the individuals’ movement, sensory perception, social interactions, cognition, memorization, and could inform on the individuals’ adaptation to these effects and on their dependence on the drug consumption. We could also explain how (the manner according which) the drug loses its effect after weaning. All this can be useful to practitioners and pharmacists. The six drugs, the side effects of which we studied and here summarized are, successively, dextromethorphan, amitriptylin, escitalopram, fluvoxamine, ivermectin, indapamide. Before relating our works, we below report medicinal information about these six largely used drugs.

Dextromethorphan is the dextrogyre enantioner of levomethorphan which is an opioid analgesic. It acts as a central cough suppressant. Assessing the efficiency of dextromethorphan and codeine versus placebo revealed that the two products significantly reduce the cough intensity. Other clinical studies also pointed out the efficiency of dextromethorphan (e.g.14,15) while other ones did not (e.g.16,17,18) maybe due to the smallness of the samples. Adverse effects have been mentioned for dextromethorphan consumption such as nausea, blurred vision, dizziness, sedation, cases of overdose which leaded to addiction, paranoia, decrease of motor coordination. Nothing is reported as for the impact of dextromethorphan on the individuals’ cognition, learning, memorization, social relationships and adaptation to side effects, a gap our work on ants tempted to fill.

Amitriptylin is an antidepressant belonging to the less toxic category, the TCA (tricyclic) one. It seems to be rather efficient with not severe side effects, and it also allows treating children’s urinary-incontinency. The most observed side effects of amitriptylin are e.g. behavioral impairments, tiredness, confusion, headache, and thirst. Working on ants, we brought information on its effect on, among others, the individuals’ locomotion, social relationships, cognition, adaptation, habituation and dependence.

Escitalopram is also an antidepressant, but more efficient and causing more adverse effects than amitriptylin. It is an inhibitor of the serotonin recapture (an SSR). Nowadays, due to the social troubles caused by the Covid-19 pandemic, more and more persons need such ‘strong’ antidepressants. Escitalopram has been proved to be efficient, even for elderly persons, and to be rather well tolerated by patients. However, several impairments caused by its consumption are reported in the notice joined to escitalopram packages. Among these impairments, let cite headache, muscular pain, tiredness, visual perception problems, aggressiveness, confusion. Nothing is mentioned as for the impact of the drug on the individuals’ locomotion, social relationships, cognition, learning, memorization, adaptation, dependence, and loss of effects after weaning. For filling this gap, we examined as usually the impact of escitalopram on ants’ physiological and ethological traits.

Fluvoxamine is again an SSR antidepressant, efficient, but it can also be used for treating non depressive central nervous system disorders, and it was recently found to help caring of persons suffering from the Covid-19 illness. Information on fluvoxamine can be found in the reviews. Nevertheless, little information on...
the impairments of this drug is available, and we thus studied such potential effects of fluvoxamine on ants’ physiological and ethological traits, as usually.

Ivermectin, a macrocyclic lactone, is an efficient antihelmintical drug used for caring of patients suffering from, among others, loaloase, onchocerciasis, and as well as galla, and it was exceptionally found (it is an example of serendipity!) to help treating persons suffering from the Covid-19 illness, even if this is not yet unanimously admitted. Though the side effects of ivermectin occurring during antihelmintical treatments are rather well known (e.g. treated persons suffer from weakness, drowsiness, tremors, mental disorders), those which may appear in patients treated for their Covid-19 illness have not yet been carefully, sufficiently examined. We thus studied, as usually, potential impacts of ivermectin on several physiological and ethological traits of ants.

Indapamide is a sulfonamide used for caring of persons suffering from hypertension, edema, or some heart dysfunction and appears to be efficient. In the notice joined to this drug packages, several side effects are mentioned, e.g. headache, tiredness, weakness, tottering. Since indapamide decreases the levels of sodium and potassium, it may alter the ionic blood concentration and consequently affect several physiological and ethological traits not considered in the notice nor on internet links devoted to this drug. We thus studied such potential impacts of indapamide on ants as models; we examined their adaptation to and their dependence on indapamide, and we defined the loss of the effect of indapamide after weaning.

In the discussion section, two other drugs, the effects of which we did not studied, are also mentioned and commented.

**Material and methods**

Since we have largely explained our experimental protocols in 47 works on drugs side effects, and since the present paper summarizes six new such works which again report these protocols, we here only very briefly relate these many times used and explained protocols.

**Collection and maintenance of ants**

The ants have been collected from several regions located in Belgium: the Aise valley (Ardenne), Olloy-sur-Viroin (Ardenne), Marchin (Condroz) and Visé (Basse-Meuse). Each colony was maintained in 1 to 3 glass tubes which contained water and a cotton plug. These tubes were set in a tray in which food, consisting in sugar water and *Tenebrio molitor* larvae, was delivered several times per week. The lighting of the laboratory was 110 lux while not working on ants, and 330 lux when caring of or experimenting on them. The humidity equalled about 80%, the temperature 20°C and the electromagnetic field 2µW/m².

**Drugs supply and drug solutions given to the ants**

The six studied drugs were provided by the pharmacist Wera (whose pharmacy is located at 1170 Bruxelles, Belgium), in their standard package which contained the notice for their use. A given amount of each drug was duly crushed and dissolved in a precise volume of sugared water, in order to obtain a solution ten times more concentrated than the solution daily consumed by humans. Indeed, insects and thus ants, due to their anatomy and physiology, drink ten less water than mammals including humans. The drug solution was given to the ants in their usual cotton plugged tubes. The plug was humidified and the entire solution renewed as necessary.

**Traits examined in ants**

The physiological and ethological traits which could be impacted by the drugs and which we examined on ants were the meat intake, sugar water consumption, general activity, linear and angular speeds of locomotion, orientation ability, audacity, tactile (pain) perception, brood caring, social relationships, stress and cognition (through escaping behavior), cognition (through the ability to cross a twists and turns path), conditioning acquisition, memory, adaptation to the side effects of the product, habituation to its wanted effect if possible, dependence on the drug consumption, decrease and loss of the effect of the drug after its consumption was stopped. For each studied drug, their impact on all these traits has been examined. However, since the present paper is a summary of our findings, only the most important impacts are here reported.

**Assessment of the ants’ traits**

Each trait was assessed according to a protocol and a statistical analysis set up since eight years and explained in 53 publications (47 already published in 5 summaries and 6 summarized in the present paper). Re-describing our methods would be redundant and would burden the present summary. We invite readers to take cognizance of our experimental processes in our previously published paper.

**Results**

**Dextromethorphan**

This cough drug appeared to reduce the ants’ food intake and general activity. It also enlarged their sinuosity of movement and appeared to be efficient. In the notice joined to this drug, this drug leaded to dependence, the ants preferring a solution containing the drug to a drug-free solution (Figure 1 A). The effect of dextromethorphan linearly vanished in 10 hours (so rather rapidly) after weaning, according to the linear function:

\[ E_i = E_i - 8.17 t \]

with \( E_i = \) effect at time \( t \); \( E_i = \) initial effect and \( t = \) time in hours.

All this leads to some comments reported in the discussion section.

**Amitriptylin**

The antidepressant amitriptylin had a lot of side effects in ants. It decreased their food intake, general activity, locomotion, orientation ability, tactile (pain) perception, brood caring and aggressiveness between congeners (Figure 1 B) and so their social relationships, their cognition, ability to escape from an enclosure (Table 1, line 2), and conditioning acquisition. The ants slowly, slightly adapted themselves to the effects of amitriptylin and became habituated to them. They did not develop dependence on this drug consumption. The drug had still some effect 33 hours after weaning and fully lost its effect in a total of 36 hours according to the function:

\[ E_t = E_i - 2.5 t \]

with \( E_i = \) effect at time \( t \); \( E_i = \) initial effect and \( t = \) time in hours.

So many adverse effects should be considered when treating humans with amitriptylin, an advice commented in the discussion section.
Table 1 An observed effect (on twelve examined ones) for each of the six studied drugs

| Drug, examined trait                                      | Normal diet (%) | Diet with the drug (%) |
|-----------------------------------------------------------|-----------------|------------------------|
| Dextromethorphan: aggression between congeners            | a = 0.14        | a = 0.79               |
| Amitriptyline: number of ants among 12 escaped in 12 minutes | 12              | 3                      |
| Escitalopram: number of ants in front and beyond a twists and turns path after 12 minutes | in front: 11     | in front: 16           |
|                                                          | beyond: 7       | beyond: 2              |
| Fluvoxamine: mean numbers of ants active, on the meat, and on the sugar water | 12.67 1.71 1.96 | 4.38 0.46 0.50         |
| Ivermectin: ants’ linear speed                           | 10.3 mm/s       | 6.0 mm/s               |
| Indapamide: score after 72 training hours                 | 85%             | 90%                    |
| score 72 hours after the cue removal                     | 80%             | 80%                    |

Some more information is given in the results section, and all the available one can be found in the six works relative to these drugs. The observed effects reported in the table successively concerns the aggression between nestmates, the escaping ability, the ability to cross a difficult path (i.e., the cognition), the general activity and the food consumption, the linear speed, the learning and memorization. The five first traits were decreased by the drug; the sixth one was not impacted. mm/s = millimeter per second; % = percentage

Excitalopram

Being an SSRI antidepressant, excitalopram of course caused many side adverse effects. It decreased the ants’ food intake, general activity, locomotion, orientation ability, tactile (pain) perception, brood caring and aggressiveness towards nestmates (impacting so their social relationships), their cognition (Table 1, line 3; Figure 1 C) and conditioning acquisition. The ants did not adapt themselves to these side effects, but did not become dependent on excitalopram consumption. After weaning, the effect of excitalopram stayed significantly similar to its initial one during 18 hours, became different from it though still differing from the control situation during a total of about 30 hours, and fully vanished in 36 hours. This decrease could be best described by the linear function: \( E_t = E_i - 0.33 \ t \) with \( E_i = \) effect at time \( t \); \( E_i = \) initial effect and \( t = \) time in hours.

Comments on these findings and comparison with other researchers’ observations are given in the discussion section.

Fluvoxamine

Fluvoxamine, a SSRI antidepressant nowadays also used for caring of persons suffering from the Covid-19 illness, induced several adverse effects in ants. It decreased these insects’ food intake (Table 1, line 4), largely impacted their locomotion (Figure 1 D), orientation ability, audacity (Figure 1 D), tactile (pain) perception, brood caring and aggressiveness against nestmates (so their social relationships), their cognition, their conditioning acquisition and thus their short-term memory. The ants did not adapt themselves to these side effects: they were still largely affected after ten days under the drug diet. The ants did not develop dependence on fluvoxamine consumption. After weaning, the effect of fluvoxamine slowly decreased: it kept its effect during about 12 hours, had then a slight effect during 6 more hours, and reached a non-significant effect in 36 hours. The drug entirely lost its effect in 12 more hours, so in a total of 33 hours. This decrease could be best described by the quadratic function:

\[ E_t = 198.76 - 1.13 \ t - 0.03 \ t^2 \] with \( E_i = \) effect at time \( t \); \( E_i = \) initial effect in hours (and \( R^2 = 0.984)\)

In the discussion section, these findings are commented and compared with those available in the literature.

Ivermectin

Ivermectin, an efficient antihelmintical drug which was recently successfully used for caring of persons suffering from the Covid-19, had several side effects in ants. It decreased or impacted these insects’ meat and sugar water intake, activity, locomotion, orientation ability, tactile (pain) perception, brood caring and relations with nestmates, cognition and short-term memory (Figure 1 E). The ants did not adapt themselves to these side effects, but did not develop dependence on ivermectin consumption. After weaning, the drug kept its effect during 5 hours, and then partly lost it during 12 more hours though still differing from the control situation. The effect of the drug became statistically similar to the control one in 7 more hours, and the drug entirely lost its effect in 6 more hours. Therefore, the effect of ivermectin fully vanished in a total of 30 hours, and this occurred according to a quadratic function that could be written like:

\[ E_t = E_i - 0.022 \ t^2 \]

with \( t = \) time (in hours), \( E_i = \) effect at time ‘\( t’; \( E_i = \) initial effect

Comments, comparison with available information on the drug use and advices for its use are given in the discussion section.

Indapamide

The drug indapamide, used in humans for treating hypertension, edema and cardiac problems, caused a few physiological and ethological impairments in ants. It significantly reduced or impacted their food intake, general activity, audacity, sensory (tactile and olfactory) (Figure 1 Fb) perception, brood caring (Figure 1 Fa) and interaction with congeners (so their social relationships). Indapamide did not affect the ants’ state of stress, cognition (Figure 1 Fc), conditioning acquisition and memorization (Table 1, line 6). The ants never adapted themselves to the side effects of the drug, but they developed no dependence on its consumption. After weaning, the effect of indapamide firstly slowly decreased, being still similar to the initial one after 8 hours. It then stayed different from the control situation during 8 more hours. After that, it somewhat more rapidly decreased and vanished in 8 more hours. Indapamide lost thus fully its effect in a total of 24 hours according to a quadratic function of the time that could be written as:

\[ E_t = E_i - 0.03 \ t^2 \]

with \( t = \) time (in hours), \( E_i = \) effect at time ‘\( t’; \( E_i = \) initial effect

During this decrease, as well as during the study of each examined trait, a large individual variability was observed. Humans should be best treated case-by-case. This advice and some comments about the use of indapamide are given in the discussion section.

Citation: Cammaerts MC. Side effects of drugs studied on ant models: a mini review. MOJ Biol Med. 2022;7(1):1–7. DOI: 10.15406/mojbm.2022.07.00156
Concerning dextromethorphan, an excellent agreement could be observed between our findings and the information available on the side effects of this cough drug. Also, our results about the ants’ dependence on dextromethorphan and the loss of the drug effect after weaning were in agreement with what is observed in humans respectively.\textsuperscript{19,20} Attention must thus be paid to humans consuming dextromethorphan in order to prevent them from becoming dependent on it. Finally, let us add that natural products such as honey, thyme, propolis, can calm cough, and that cough is a vital reflect which allows clearing congested respiratory track.

Amitriptylin is an antidepressant also used for treating children’s urinary-incontinency troubles and some neuropathic pains. It allows preventing migraine better than other drugs,\textsuperscript{21} but presents harmful side effects.\textsuperscript{22} Our work in ants confirmed the existence of these side effects and moreover revealed the potential occurrence of a few other ones. Therefore, since amitriptylin is an efficient drug less toxic than other stronger antidepressants, it should be used, but at widely spaced doses, and the patients should be monitored as for their food intake, social relationships, cognition, memory, and habituation to the positive effect of the drug.

Escitalopram is an efficient antidepressant with apparently less toxic effects than other similar drugs.\textsuperscript{23} Nevertheless, it had adverse effects in ants, and those we found are in agreement with those reported in the literature.\textsuperscript{52,53,64} In ants, we could not examine the individuals’ potential habituation to wanted effects of the drug. Therefore, this should be studied in humans because if habituation occurs, humans will be tempted to increase their daily dose what would accentuate the drug side effects.

Fluvoxamine is an efficient antidepressant and may soon be used for treating the Covid-19 illness; it is a valuable drug.\textsuperscript{65,66} However, in ants, we found it induced many severe effects. Some of them have been reported in humans;\textsuperscript{66,67} other ones have not yet been observed, but they may occur. Therefore, we advise to monitor patients treated with fluvoxamine as for their appetite, activity, sensory perception, social relationships, cognition and memorization. Also, it should be checked if these patients become habituated to the researched effect of fluvoxamine, because if this occurs, the patients will be tempted to increase their drug dose, and doing so would accentuate the drug side effects. In addition, some concordance appeared between our findings on the loss of the effect of fluvoxamine after weaning and what was observed as for this topic in humans.\textsuperscript{68,69} On the basis of these findings, we propose to care of patients thanks to a daily dose of 100 g every 36 hours (and not every 24 hours as it is currently the case), what would allow limiting the drug side effects.

The side effects of ivermectin used as an anthelminthical drug are rather well known, but those which may occur while using it to treat persons suffering from or susceptible to contract the Covid-19 are not precisely know until now. Ants maintained under an ivermectin diet presented several physiological and ethological impairments which may occur in humans. Therefore, before massively using ivermectin, we recommend to make duly conducted medicinal studies in order to examine the occurrence of side effects and to define the most appropriate daily dose. As for this last point, the decrease of the wanted effect of ivermectin should be established, and patients’ potential habituation to such wanted effect should be examined. In addition, ivermectin is very toxic for the environment, especially for the insects.\textsuperscript{70} Systems for eliminating the drug residues from waste water should be set up before world widely using it for significantly decreasing the nowadays Covid-19 pandemic.

Due to its mode of action and its low diuretic effects, indapamide had in ants not much severe adverse effects, what is also the case for humans.\textsuperscript{50,51,52} For instance, indapamide did not impact the ants’ cognition, learning and memorization. This finding is in agreement with the improved impact of the drug on the brain functioning of patients having had cerebrovascular diseases.\textsuperscript{71} Nevertheless, we found that indapamide had several physiological and ethological impairments in ants not much severe adverse effects, what is also the case in literature.\textsuperscript{68,69} On the basis of these findings, we propose to care of patients thanks to a daily dose of 100 g every 36 hours (and not every 24 hours as it is currently the case), what would allow limiting the drug side effects.

The side effects of ivermectin used as an antihelminthical drug are rather well known, but those which may occur while using it to treat persons suffering from or susceptible to contract the Covid-19 are not precisely know until now. Ants maintained under an ivermectin diet presented several physiological and ethological impairments which may occur in humans. Therefore, before massively using ivermectin, we recommend to make duly conducted medicinal studies in order to examine the occurrence of side effects and to define the most appropriate daily dose. As for this last point, the decrease of the wanted effect of ivermectin should be established, and patients’ potential habituation to such wanted effect should be examined. In addition, ivermectin is very toxic for the environment, especially for the insects.\textsuperscript{70} Systems for eliminating the drug residues from waste water should be set up before world widely using it for significantly decreasing the nowadays Covid-19 pandemic.

Due to its mode of action and its low diuretic effects, indapamide had in ants not much severe adverse effects, what is also the case for humans.\textsuperscript{50,51,52} For instance, indapamide did not impact the ants’ cognition, learning and memorization. This finding is in agreement with the improved impact of the drug on the brain functioning of patients having had cerebrovascular diseases.\textsuperscript{71} Nevertheless, we found that indapamide had several side effects which should be examined in humans. These effects are, among others, impairments of food intake, activity, locomotion, sensory perception, and social relationships.
These effects may be due to the lowering of the calcium and the potassium levels induced by the drug.3 In addition to the exam in humans of the side effects observed in ants, we estimate that humans’ potential habituation to the researched effect of indapamide should be examined, and that patients should be treated case-by-case (e.g. for defining their daily dose) since in ants a large individual variability has been observed. Even if not editable, we want to affirm that, being under an indapamide diet since one year, we very obviously feel some changes in our physiology and ethology fully in agreement with what we found in ants. We suffer from tiredness, weakness while moving, and have some social relationships troubles, no longer appreciating the presence of parents and friends.

To finish, we give our opinion on two drugs we did not studied since they are not yet available in Belgium (our country), but which may soon be used to treat patients suffering from the Covid-19 illness. Peritonitis of felines is due to a corona virus and is treated thanks to the drug remdesivir. Therefore, practitioners have tried to use this drug for caring of humans having the Covid-19 illness. Remdesivir seemed to be rather efficient, but this must yet be confirmed through uses of the drug and medicinal experimentations. We want to point out that domestic cats often suffer from kidney illness and that, unfortunately, for cats, remdesivir appeared to be toxic for this organ. Consequently, remdesivir should no longer be used for caring of cats suffering from peritonitis. Molnupiravir is a drug newly used for treating the Covid-19, but more essays, medicinal researches and observations are required for affirming its efficiency. Nevertheless, due to its mode of action, this drug largely reduces the propagation of the virus, and is thus very promising.

Conclusion

After having published five summaries relating our previous studies of 47 products used by humans, we here present a summary of our six last studies on drugs. We used ants as models, as usually, confirmed the side effects observed in humans, and revealed other not yet observed ones. Practitioners and pharmacists should take our findings and advices into account while using one or the other of these six drugs. The present work is only a summary, a ‘mini review’; the entire works are published in and can be asked directly to the author(s). Using ants as models turned out being successful, not expensive, rather easy, and moreover presenting very little ethical consideration. A final advantage would be to provide significant information to medical science.

Our future research projects are the studies of diuretics having less side effects than indapamide, of novelty used antidepressants (the consumption of which nowadays increases), and of drugs recently used for caring of persons suffering from the Covid-19 which still spreads.

Acknowledgments

We sincerely thank Roger Cammaerts and David Cammaerts who helped us with the statistical analysis, the writing and the bibliography of our works, which would not have been what they are without their help.

Conflicts of interest

We declare having no conflict of interest as for the manufacture, the sell and the use of the drugs we studied. We work on ants, on their behavior, cognition and ontogenesis of abilities, we use them as biological models for studying products consumed by humans, and we receive no money for making our research.

References

1. Cammaerts MC. Ants as biological models for studying effects of substances used by humans. JSM Anat Physiol. 2016;1:1003–1008.
2. Cammaerts MC. Some findings on ants as models, which should be considered for caring of humans. MOJ Biol Med. 2017;1(5):00027.
3. Cammaerts MC. Ants as models for examining potential adverse effects of products used by humans. JSM Anat Physiol. 2018;3(1):1016.
4. Cammaerts MC. Brief report of the effects of seven human drugs studied on ants as models. MOJ Biol Med. 2019;4(2):42–47.
5. Cammaerts MC, Cammaerts R. Summary of seven more studies on numerosity abilities in an ant, four of them relating to human competence. J Biol and Life Sciences. 2020;11(2):296–326.
6. Cammaerts MC, Cammaerts R. Side effects of the cough drug dextromethorphan, studied on ants as models. MOJ Biol Med 2021; 6(1):40–50.
7. Cammaerts MC, Cammaerts D. Amitriptyline: side effects of a largely used antidepressant evaluated on ants as biological models. Acta Scientific Pharmaceutical Sciences. 2021;5(5):13–30.
8. Cammaerts MC. Physiological and ethological impacts of the antidepressant escitalopram studied on ants as models. Acta Sci. Pharma. Sci. 2021;5(6):02-16.
9. Cammaerts MC, Cammaerts R. Side effects, studied on ants as models, of fluvoxamine nowadays used for treating persons suffering from the Covid-19.ECPT. 2021,9(11):03–25.
10. Cammaerts MC. Side effects of ivermectin, a drug recently used to treat humans suffering from the Covid-19 illness, a study on ants as models. ASPharma2021;2(10):40–53.
11. Cammaerts MC. Side effects of the largely used drug indapamide; a study on ants as models. AS Pharmaco. 1975;3(3):138–144.
12. Dipinigaitis P, Morice A, Birring S, et al. Antitussive drugs – Past, present and future. Pharmaco Rev. 2014;66:468–512.
13. Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: Objective assessment of antitussive activity in patients with chronic cough. J Int Med Res. 1983;11:92–100.
14. Parvez L, Vaidya M, Sakhardande A, et al. Evaluation of antitussive agents in man. Palm Pharmaco. 1996;9:299–308.
15. Pavesi L, Subburaj S, Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: A meta-analysis. CHEST. 2001;120:1121–1128.
16. Tukanen H, Karttunen P, Silvasti M, et al. The treatment of acute transient cough: A placebo-controlled comparison of dextromethorphan and dextromethorphan-beta2-sympathomimetic combination. Eur J Respir Dis. 1986;69(2):95–99.
17. Korppi M, Laurikainen K, Pietikainen M, et al. Antitussives in the treatment of acute transient cough in children. Acta Paediatr Scand. 1991;80:969–971.
18. Lee P, Jawad M, Eccles R. Antitussive efficacy of dextromethorphan with acute upper respiratory tract infection. JPP. 2000;52(89):1137–1142.
19. Rühle K, Crisciudo D, Dieterich H, et al. Objective evaluation of dextromethorphan and glaucine as antitussives. Br J Clin Pharmac. 1984;17:521–524.
20. Desai S, Aldea D, Daneels E, et al. Chronic addiction to dextromethorphan cough syrup: A case report. JABFM. 2006;19(3):320–323.
21. Martinak B, Bolis R, Black J, et al. Dextromethorphan in cough syrup: The poor man’s psychosis. Psychopharmacol Bull. 2017;47(4):59–63.
22. Dextromethorphan. 2021.
23. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018

24. fr.wikipedia.org/wiki-Amitruptiline

25. Mitchell B Max, Sue A Lynch, Joanne Muir RN, et al. Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy. N Engl J Med. 1992;326:1250–1256.

26. Gorman JM, Koroatzer A. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectrum. 2002;7:40–44.

27. Kennedy SH, Anderson HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neuurosci. 2006;31(2):122–131.

28. Burke WJ, Gregel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331–336.

29. Bélïcard C, Manckoundia PP, Ponavy E et al. Antidepressant use in demented elderly subjects: current data. La Revue de Médecine Psychologique. 2000;30(11):947–954.

30. Wades A, Lemming OM, Hedegaard KB. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International J Clin Psychopharmacol. 2001;17(3):95–102.

31. Lepola UM, Loft H, Reines EH. Escitalopram (10-20mg/DAY) is effective and well tolerated in a placebo controlled study in depression in primary care. Int J Clin Psychopharmacol. 2003;18(4):211–217.

32. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32:313–334.

33. Sutherland JE, Sutherland SJ, Hoehns JD. Achieving the best outcome in treatment of depression. J Family Practice. 2003;52(3):201–209.

34. Perse TL, Greist JH, Jefferson JW. et al. Fluvoxamine treatment of obsessive-compulsive disorder Am J Psychiatry. 1987;144(12):1543–1548.

35. Goodman WK, Price LH, Rasmussen SA. et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46(1):36–44.

36. Palmer KJ, Benfield P. Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs. 2004;1:57–87.

37. Lenze EJ, Mattar C, Zoromski CF et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA. 2020;324(22):2292–2300.

38. Seffiel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2).

39. Hoertel N, Sanchez-Rico M, Vernet R et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from and observational study. Mol Psychiatry. 2021;26:5199–5212.

40. Wilde MJ, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology and therapeutic use in depressive illness Drugs. 1993;46:895–924.

41. Figgitt DP, McIleran KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs. 2000;60(4):925–954.

42. Caumes E, Danis M. New indications for ivermectin. La revue de Médecine Interne. 2001;22(4):379–384.

43. Develoux M. Ivermectine. Ann Dermatol Venéréol. 2004;131:561–570.

44. Bemisgaard C, Guillermot D, Ahmed-Belkacem A et al. Bénéfice de l’ivermectine : de la galle à la COVID-19, un exemple de sérendipité. Ann Dermatol Venéréol. 2020;147:A194.

45. Caly L, Duce JD, Catton MG, et al. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178.

46. Kory P, Meduri GU, Varon J et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. American J Therapeutics. 2021;28(3):e299–e318.

47. Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. EBM opinion and debate. 2021;22.

48. Sargas A, Bonnetblanc JM, Peyrot I et al. Effets secondaires de l’ivermectine utilisée dans le traitement de la galle. Ann Dermatol Venéréol. 2005,133(10):784–787.

49. Ducorps M, Gardon-Nendel N, Ranque S et al. Effets secondaires de la treatment de la loase hyper microfilarémique par l’ivermectine. Bull Soc Pathol Exot. 1995;88(3):105–112.

50. Chaffman M, Heel RC, Brogden RN et al. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 2012;28:189–235.

51. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Clin Pharmacokinet. 2012;51:7–12.

52. Moore RA, Seki T, Ohsumi S et al. Antihypertensive action of indapamide and review of pharmacology and toxicology. Curr Med Res Opin. 1977;5:25–32.

53. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol. 1990;65(17):H11–H27.

54. Chalmers J, Mourad JJ, De Champyallins M et al. Benefit of indapamide-based treatment on mortality. J Hypertens. 2019;37:e57.

55. Suchard MA, Schuenie MJ, Krumholz HM et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug-classes: a systematic, multinational, large-scale analysis. The Lancet. 2019;394(10211):1816–1826.

56. Chapman MD, Hansen R, McEwen J, et al. Hyponatraemia and hypokalaemia due to indapamide. Med J Aust. 2002;176(5):219–221.

57. Dextromethorphan. 2020.

58. Desai S, Aldea D, Danels E, et al. Chronic addiction to dextromethorphan cough syrup: A case report. JABFM. 2006;19(3):320–323.

59. Amelin AV, Skoromets AA, Korenko LA et al. A comparative efficiency of amitryptiline, fluoxetine and maprotiline in prevention of migraine in attack-free period. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2000;100(8):20–23.

60. Marsh W. Amitriptyline – an overview. Chapter in Medical Pharmacology and Therapeutics. 5th ed. 2018.

61. Burke WJ. Escitalopram Expert Opinion on Investigational Drugs 2002;11(10):1477–1486.

62. Otto M, Bach FW, Jensen TS et al. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain. 2008;139(2):275–283.

63. Druke B, Baetz J, Boecker M et al. Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. Psychopharmacology. 2009;207(2):213–223.

64. Coskun M, Ozturk M, Zoroglu S. Escitalopram treatment in preschool children with anxiety disorders: a case series. Bulletin of Clinical Psychopharmacology. 2012;22(3):262–267.

65. Medscape data base.
66. Cheer SM, Figgitt DP. Fluvoxamine. A review of its therapeutic potential in the management of anxiety disorders in children and adolescents. *Paediatric Drugs.* 2001;3(10):763–781.

67. Hoehn-Saric R, Lipsy JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. *Journal of Clinical Psychopharmacology.* 1990;10(5):343–345.

68. Strauss WL, Layton ME, Dager SR. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. *The Am J Psychiatry.* 1998;155(3):380–384.

69. Bolo NR, Hodé Y, Nédélec JF et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. *Neuropsychopharmacology.* 2000;23(4):428–438.

70. Azzi A. *Ivermectine: pharmacologie, toxicologie, efficacité clinique et impact sur l’environnement* Thesis, Direction de la programmation et des affaires économiques, Ministère de l’agriculture, du développement rural et des pêches maritimes. 1994. 84p.

71. The PROGRESS Collaborative Group. “Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease.” *Archives of Internal Medicine.* 2003;163(9):1069–1075.

72. Lamb YN. Remdesivir: First Approval. *Drugs.* 2020;80:1355–1363.

73. Malone B, Campbell EA. Molnupiravir: coding for catastrophe. *Nat Struct Mol Biol.* 2021; 28:706–708.